Skip to main content Accessibility help
×
×
Home

DOSAGE AND DURATION OF ETANERCEPT THERAPY FOR ANKYLOSING SPONDYLITIS: A META-ANALYSIS

  • Heeyoung Lee (a1), Younjoo Jung (a1) (a2), Seungyeon Song (a1), Jihyung Lee (a1), Hyunjun Shim (a3), Wonku Kang (a4) and Eunyoung Kim (a1) (a3) (a5)...

Abstract

Objectives: We conducted a meta-analysis of recently published randomized controlled trials (RCTs) to identify the most effective and safe etanercept dosing regimen and duration of therapy for the treatment of patients with ankylosing spondylitis (AS).

Methods: We systematically reviewed PubMed, Embase, Cochrane Library, and Web of Science databases for RCTs. The proportion of patients attaining 20 percent improvement (according to the Spondyloarthritis International Society response criteria [ASAS 20]) was evaluated as a primary outcome. Secondary outcomes included 50 percent increase in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50) used for evaluating efficacy, as well as the BASDAI/Bath Ankylosing Spondylitis Functional Index (BASFI) scores and adverse events.

Results: ASAS 20 indicated that the efficacy of etanercept did not differ amongst dosing regimens (25 mg twice-weekly versus 50 mg once-weekly: relative risk [RR], 2.18, 95 percent confidence interval [CI], 1.78–2.67 versus RR, 2.00, 95 percent CI, 1.70–2.37). The ASAS 20 reported subgroup differences among treatment durations of less than 12 weeks (RR, 2.70; 95 percent CI, 2.09–3.49); 12 weeks (RR, 1.74; 95 percent CI, 1.37–2.22); and more than 12 weeks (RR, 2.56; 95 percent CI, 1.88–3.48). Other outcomes included BASDAI, BASDAI 50, and BASFI. Drug safety differed according to the treatment regimen and duration.

Conclusion: Our meta-analysis found that there was no significant efficacy difference between 50 mg once-weekly and 25 mg twice-weekly dosing for the treatment of AS, and a dosing duration of less than 12 weeks was more effective for treating AS patients.

Copyright

References

Hide All
1. Rudwaleit, M, Listing, J, Brandt, J, Braun, J, Sieper, J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63:665670.
2. Navarro-Sarabia, F, Fernandez-Sueiro, JL, Torre-Alonso, JC, et al. High-dose etanercept in ankylosing spondylitis: Results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford). 2011;50:18281837.
3. Goldenberg, MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21:7587; discussion 1-2.
4. FDA/Center for Drug Evaluation and Research. Label information. Silver Spring, MD: FDA; 2013.
5. Maxwell, SR. Evidence based prescribing. BMJ. 2005;331:247248.
6. McCormack, PL, Wellington, K. Etanercept: In ankylosing spondylitis. BioDrugs. 2004;18:199205; discussion 06.
7. Li, ZH, Zhang, Y, Wang, J, Shi, ZJ. Etanercept in the treatment of ankylsoing spondylitis: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 2013;23:497506.
8. Baji, P, Pentek, M, Szanto, S, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: Systematic literature review and meta-analysis. Eur J Health Econ. 2014;15 (Suppl 1):S45S52.
9. Maxwell, LJ, Zochling, J, Boonen, A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:cd005468.
10. Sieper, J, Rudwaleit, M, Baraliakos, X, et al. The Assessment of SpondyloArthritis International Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:144.
11. Green, S, Higgins, JPT, Alderson, P, et al. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. p. www.Cochrane-handbook.org-www.Cochrane-handbook.org.
12. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009;339:b2535.
13. Moher, D, Cook, DJ, Eastwood, S, Olkin, I, Rennie, D, Stroup, DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896–1900.
14. Egger, M, Davey Smith, G, Schneider, M, Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629634.
15. Duval, S, Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455463.
16. Dougados, M, Braun, J, Szanto, S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: Results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 2011;70:799804.
17. Dougados, M, van der Heijde, D, Sieper, J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: A multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66:20912102.
18. Calin, A, Dijkmans, BA, Emery, P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004;63:15941600.
19. Pang, L, Wang, L, Suo, T, et al. Tumor necrosis factor-alpha blockade leads to decreased peripheral T cell reactivity and increased dendritic cell number in peripheral blood of patients with ankylosing spondylitis. J Rheumatol. 2008;35:22202228.
20. JC, Davis Jr, Van Der Heijde, D, Braun, J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum. 2003;48:32303236.
21. Lin, Q, Lin, Z, Gu, J, et al. Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment. Rheumatol Int. 2010;30:317323.
22. van der Heijde, D, Da Silva, JC, Dougados, M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:15721577.
23. Gorman, J.D, Sack, K.E. & Davis, J.C Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002, 346 (18), 1349-56.
24. Brandt, J, Khariouzov, A, Listing, J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:16671675.
25. Barkham, N, Coates, LC, Keen, H, et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis. 2010;69:19261928.
26. Huang, F, Zhang, J, Huang, JL, et al. A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis. Zhonghua Nei Ke Za Zhi. 2010;49:741745.
27. Taylor, WJ, Harrison, AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum. 2004;51:311315.
28. Shu, T, Chen, GH, Rong, L, et al. Indirect comparison of anti-TNF-α agents for active ankylosing spondylitis: Mixed treatment comparison of randomized controlled trials. Clin Exp Rheumatol. 2013;31:717722.
29. Machado, MA, Baarbosa, MM, Almeida, AM, et al. Treatment of ankylosing spondylitis with TNF blockers: A meta-analysis. Rheumatol Int. 2013;33:21992213.
30. Brandt, J, Listing, J, Haibel, H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford), 2005;44:342348.
31. Wallis, D, Haroon, N, Ayearst, R, Carty, A, Inman, RD. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: Part of a common spectrum or distinct diseases? J Rheumatol. 2013;40:20382041.
32. Bavbek, S, Ataman, S, Bankova, L, Castells, M. Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation. Allergol Immunopathol (Madr). 2013;41:204206.
33. Moore, Z. Meta-analysis in context. J Clin Nurs. 2012;21:27982807.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Type Description Title
UNKNOWN
Supplementary materials

Lee supplementary material
Figure S1

 Unknown (129 KB)
129 KB
WORD
Supplementary materials

Lee supplementary material
Tables S1-S3

 Word (17 KB)
17 KB

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed